WIRE — Macquarie and HSBC remained positive on Sun Pharma after June-quarter EBITDA and margins beat estimates, while BofA flagged slowing US and specialty sales and limited near-term catalysts.
"We aggregate wires to encourage regional discovery, sending readers directly back to the original source to explore full coverage."
This is a normalized overview of the breaking feed event. The complete, official release detailing all points, background context, and statements remains hosted by the original publisher.